Skip to content
Screener

Total Liabilities at other companies

Merck & Co. logo
Merck & Co.MRK
$252M
Savara logo
SavaraSVRA
$48.48M+12.0%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$1.34B-19.2%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$10.21M-13.3%
LQD
Liquidia CorporationLQDA
$292.95M+64.8%
United Therapeutics logo
United TherapeuticsUTHR
$819.8M+11.6%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.54B+184%
Enterprise value$2.52B+224%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206390
AssetsMarch 31,2026 / UnauditedDecember 31,2025
Operating lease liabilities318307
Total current liabilities7,1159,749
Operating lease liabilities364446
Total liabilities7,47910,195
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock: $0.001 par value; 5,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025.
Common stock: $0.001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; and 128,411,048 and 128,306,056 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.128128

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is Trevi Therapeutics, Inc.'s total liabilities?
Trevi Therapeutics, Inc. (TRVI) reported total liabilities of $7.48M in Q1 2026.
How has Trevi Therapeutics, Inc.'s total liabilities changed year-over-year?
Trevi Therapeutics, Inc.'s total liabilities decreased by 0.9% year-over-year, from $7.55M to $7.48M.
What is the long-term trend for Trevi Therapeutics, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s total liabilities has grown at a -12.5% compound annual growth rate (CAGR), from $19.85M to $10.2M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Trevi Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude